The FSA Spy market buzz – 11 April 2025
Lazard actively looks at Next Gen; Goldman Sachs loves active in small places; Janus Henderson is reassuring; Private equity’s overflowing war chest; Jevons Paradox; Hamlet’s wisdom and much more.
HEAD-TO-HEAD: Janus Henderson vs BNP Paribas Parvest
FSA compares the Janus Global Life Sciences Fund with the Parvest Equity World Health Care Fund
The Janus fund is the more expensive of the two, with ongoing charges (OCF) of 2.44% compared to Parvest’s 1.98%. The fees charged by healthcare funds registered for sale in Hong Kong range from 1.73% to 3.09%, with the median of 1.98%.
“Due to the specialisation of the sector, the fees tend to be high,” Ng said. “If you invest in this sector, you need to accept that.”
Related Stories
Promoted Content
-
How ETFs offer an active way to drive sustainable returns
-
Tech WELLcovered | Work reimagined
-
Smartphones on wheels
-
The future of mobility
-
Thematic investment series: Innovative transformation cuts across “old” and “new” economy companies
-
Federated Hermes SDG Engagement Equity: 2021 H1 Report
-
Sustainable Investing in Changing Market Conditions
-
Who’s afraid of higher interest rates?
-
Appetite for thematic investments grows amid rates and inflation concerns
-
How can a sustainable approach also ensure you don’t compromise performance?
